Evidence map›Paper›PMID 31408538›Full record

ArticleAllergy2020

Apolipoprotein A-IV acts as an endogenous anti-inflammatory protein and is reduced in treatment-naïve allergic patients and allergen-challenged mice.

David Roula, Anna Theiler, Petra Luschnig, Gunter J Sturm, Peter V Tomazic, Gunther Marsche, Akos Heinemann, Eva M Sturm

Open access · hybridAbstract read
In one paragraph

Article in Allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Anti-inflammatory peptide therapeutics and the role of sulphur containing amino acids (cysteine and methionine) in inflammation suppression: A review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

David RoulaDivision of Pharmacology, Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, Austria.ORCID 0000-0003-0472-6784
Anna TheilerDivision of Pharmacology, Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, Austria.ORCID 0000-0001-5233-0376
Petra LuschnigDivision of Pharmacology, Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, Austria.ORCID 0000-0002-1873-645X
Gunter J SturmDepartment of Dermatology and Venerology, Medical University of Graz, Graz, Austria.ORCID 0000-0002-7245-121X
Peter V TomazicENT-University Hospital, Medical University of Graz, Graz, Austria.ORCID 0000-0001-6445-4800
Gunther MarscheDivision of Pharmacology, Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, Austria.ORCID 0000-0002-2422-5381
Akos HeinemannDivision of Pharmacology, Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, Austria.ORCID 0000-0002-8554-2372
Eva M SturmDivision of Pharmacology, Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Graz, Austria.ORCID 0000-0003-4898-884X
Medical University of Graz · AT

Funding

Austrian Academy of SciencesAustrian Science Fund DK-MOLINAustrian Science Fund W1241
6 · The paper itself

Abstract

backgroundRecent studies pointed to a crucial role for apolipoproteins in the pathogenesis of inflammatory diseases. However, the role of apolipoprotein-IV (ApoA-IV) in allergic inflammation has not been addressed thoroughly thus far.

objectiveHere, we explored the anti-inflammatory effects and underlying signaling pathways of ApoA-IV on eosinophil effector function in vitro and in vivo.

methodsMigratory responsiveness, Ca

resultsRecombinant ApoA-IV potently inhibited eosinophil responsiveness in vitro as measured by Ca

conclusionOur data suggest that ApoA-IV is an endogenous anti-inflammatory protein that potently suppresses effector cell functions in eosinophils. Thus, exogenously applied ApoA-IV may represent a novel pharmacological approach for the treatment of allergic inflammation and other eosinophil-driven disorders.

Indexed as

AdolescentAdultAllergensAnimalsAnti-Inflammatory AgentsApolipoproteins AApoptosisAsthmaCalciumCells, CulturedChemotaxisDisease Models, AnimalEosinophilsFemaleHumansMaleAllergensAnti-Inflammatory Agentsapolipoprotein A-IVApolipoproteins ACalciumallergic inflammationapolipoprotein A-IVchronic rhinosinusitiseosinophilshouse dust mite-induced asthma modelPI3-kinaseRev-Erb-α

Identifiers

PMID31408538
PMCPMC7065107
OpenAlexW2968832864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.